Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2

By afschroeder • September 27, 2025

Grinspoon SK, Zhao S, Martinez E, Fichtenbaum CJ, Chu SM, Diggs MR, Umbleja T, McCallum S, Fitch KV, Triant VA, Currier JS, Aberg JA, Malvestutto CD, Erlandson KM, Bloomfield GS, Lu MT, Douglas PS, Ribaudo HJ, Zanni MV. Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2. Clin Infect Dis. 2025 Sep 26:ciaf542. doi: 10.1093/cid/ciaf542. Epub ahead of print. PMID: 41004413.

Tags: atherosclerotic cardiovascular disease, HIV, Infectious Diseases, Publications, REPRIEVE, risk scores, statin

The Use of Genetics and Immunology in the Diagnosis and Care of Advanced Coccidioidomycosis: Where Are We Going?

Thiagarajan K, Mishra S, Purdie R, Torres B, Johnson RH, Butte MJ. The Use of Genetics and Immunology in the Diagnosis and Care of Advanced[...]

Preferences for HIV prevention conditional cash transfers among Black/African American and Latinx cisgender MSM in Los Angeles

Moucheraud C, Trujillo D, Wagner Z, Garland W, Smith T, Hoffman RM, Landovitz RJ. Preferences for HIV prevention conditional cash transfers among Black/African American and[...]

PrEPared to choose: the protocol for an implementation study of the delivery of cabotegravir long-acting injectable pre-exposure prophylaxis (PrEP) as an HIV prevention product option within a real world PrEP choice context in cape town

Pike C, Rousseau E, Macdonald P, Mapukata P, Lebelo K, Joseph-Davey D, Little F, Bekker LG. PrEPared to choose: the protocol for an implementation study[...]